Anavex Life Sciences Corp (AVXL)

[nidan7500]

Int J Mol Sci. 2020 May; 21(10): 3517.
Published online 2020 May 15. doi: 10.3390/ijms21103517
PMCID: PMC7278930
PMID: 32429229
Transcriptomics in Alzheimer’s Disease: Aspects and Challenges
Eva Bagyinszky,1,2 Vo Van Giau,1,2,* and SeongSoo A. An2,*

It will be interesting to note the reactions to the AVXL work. Since just about every research work for decades has consistently beat the Amyloid thesis drum while AVXL has consistently gone a different path.

Some may trash AVXL just b/c of the differing paths and the trheat such path may present. We shall soon see if that really matters or if the case made by AVXL is very strong and compelling. My limited experience has been that after decades (3+) of beating the same drum w/very little -no causal proof (by many, many very smart people) that drum is broken.

Maybe a new tool app will reveal a new path somehow previously not seen, missed. We'll see. IMO, insticnts tell me the UPSTREAM path presents as/is a new causal source. In any case this is going to be very interesting to watch. If AVXL have compelling stuff w/strong findings on root cause for AD and other CNS diseases I do not expect the room to light up w/congrats (even though maybe it should). .

I do expect pharma press ,BP and academics to be caught standing in the silent zone or perhaps puzzled, other. After spending a lifetime of beating a certain drum many may be inclined to simply pound their drum harder. We'll see I guess. .

Best wishes and support to the AVXL team as CNS-BP enter into a critical next phase of , "Show and Tell", for all the marbles.